PHILADELPHIA, April 18, 2015 /PRNewswire/ --
Aurigene and its partner Curis, Inc. (NASDAQ: CRIS) will be presenting data at the poster sessions from two programs at the American Associate of Cancer Research Annual Meeting (April 18-22 in Philadelphia, PA).
Aurigene will present data for its proprietary Nicotinamide phosphoribosyltransferase (NAMPT) small molecule inhibitors program, which is currently in preclinical development.
Aurigene and Curis will present data from their interleukin-1 receptor association kinase-4, or IRAK-4, inhibitor program.
Additional information on the presentations can be found below and abstracts can be accessed at http://www.aacr.org.
Title: Discovery of dihydro-isoxazole derivatives as novel inhibitors of NAMPT for the treatment of multiple myeloma
Session Category: Experimental and Molecular Therapeutics
Session Title: Drug Discovery
Session Date and Time: Wednesday April 22, 2015 8:00 AM - 12:00 PM
Abstract Number: 3647
Title: Novel IRAK-4 inhibitors exhibit highly potent anti-proliferative activity in DLBCL cell lines with activating MYD88 L265P mutation
Session Category: Chemistry
Session Title: Drug Discovery: Kinases, Nuclear Hormone Receptors, and Novel Targets
Session Date and Time: Tuesday, April 21, 2015, 8:00 AM - 12:00 PM
Abstract Number: 3646
Aurigene is a specialized, discovery stage biotechnology company, developing novel and best-in-class therapies to treat cancer and inflammatory diseases. Aurigene's Programmed Death pathway program is the first of several immune checkpoint programs that are at different stages of discovery and preclinical development. Aurigene has partnered with several large- and mid-pharma companies in the United States and Europe and has delivered multiple clinical compounds through these partnerships. With over 500 scientists, Aurigene has collaborated with 6 of the top 10 pharma companies. For more information, please visit Aurigene's website at http://aurigene.com/.
About Curis, Inc.
Curis is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. Curis' pipeline of drug candidates includes CUDC-907, a dual HDAC and PI3K inhibitor, CUDC-427, a small molecule antagonist of IAP proteins, and CUDC-305, an oral HSP90 inhibitor. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis expects to exercise options to exclusively license oral small molecule antagonists of PD-L1 and IRAK4 and file IND application for both molecules in 2015. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are developing and commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at http://www.curis.com
Director Strategic Alliances